Response Genetics, a company focused on the development and commercialization of molecular diagnostic tests for cancer, today announced the appointment of Christine Meda as the company’s president, replacing Kathleen Danenberg, who will continue to act as CEO.
Meda’s nearly 30 years of experience in strategic partnering, operations and marketing for Response Genetics will fuel her ability to help in the execution of the company’s strategy and operations on a day-to-day basis.
“I am pleased to be joining Response Genetics, a company with a unique platform technology and differentiated product offering. I look forward to applying my skills and experience knowing that I am not only providing value to the company and its shareholders, but helping improve the diagnostic information used to treat people with cancer,” Meda stated in the press release.
She previously served as CEO of early-stage molecular diagnostics company Arcxis Biotechnologies; founded and is president of RxDxLink, a consulting service for biotechnology companies; president and COO for early-stage cancer diagnostics company Diamics Inc.; as well as served several other industry-related positions.
“With her strong background in the diagnostics industry, Christine’s strategic vision and considerable business experience have helped companies successfully develop, launch and market products,” CEO Danenberg stated. “And with our current growth rate in the double digits, her addition to the senior management team will help Response Genetics expand its market and realize its growth potential.”
For more information visit www.res